Pfizer

₹5517 36.2 | 0.7%

WEBSITE BSE:500680 NSE : PFIZER LTD. 11 Jul, 15:59

Market Cap ₹25239 Cr.

Stock P/E 32.9

P/B 6

Current Price ₹5517

Book Value ₹ 921.9

Face Value 10

52W High ₹6452.9

Dividend Yield 2.99%

52W Low ₹ 3742.9

Edit Ratio

Pfizer Research see more...

Overview Inc. Year: 1950Industry: Pharmaceuticals & Drugs

Pfizer Ltd is an India-based pharmaceutical agency. The Company has a portfolio of approximately 150 products across over 15 therapeutic areas. The Company is engaged in production, advertising, buying and selling and exporting pharmaceutical products. The Company gives various merchandise for anti-diabetic, erectile disorder, gastrointestinal (GI), multivitamins, anti-infectives, cardiovascular, dermatology, neurology, ache/fever/infection and autoimmune problems, amongst others. Its merchandise consist of Viagra, Daxid, Tricorex, Mucaine, Diamox, Hetrazan, Enbrel, Ativan, Pacitane, Folvite Tablets, Autrin Capsules, Prevenar 13, Wysolone, Loette, anti-infectives, cardiovascular, dermatology, Trulimax, Vibazime DT, Ovral G, Ovral L, Premarin pills, Premarin Vaginal Cream, Zosyn, Wymox, Tygacil, Cynomycin, Targit, Cyklokapron and Magnamycin. The Company has its personal production facility at Thane and Goa. The Company has numerous impartial settlement/third party manufacturers based throughout the country.

Pfizer Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Pfizer Quarterly Results

#(Fig in Cr.)	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Net Sales	622	573	531	575	540	547	563	589	538	592
Other Income	27	31	33	36	36	75	42	43	43	45
Total Income	649	604	565	611	576	622	605	632	581	636
Total Expenditure	418	391	421	393	387	357	385	399	392	364
Operating Profit	231	213	144	219	188	265	219	232	189	272
Interest	4	3	3	3	3	7	2	2	2	3
Depreciation	26	26	16	15	18	14	15	15	15	16
Exceptional Income / Expenses	0	-20	0	0	8	0	0	0	0	173
Profit Before Tax	201	165	126	201	176	244	203	215	172	426
Provision for Tax	50	35	32	52	46	65	52	57	45	95
Profit After Tax	151	130	94	149	130	179	151	158	128	331
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	151	130	94	149	130	179	151	158	128	331
Adjusted Earnings Per Share	32.9	28.3	20.4	32.6	28.4	39.1	32.9	34.6	27.9	72.3

Pfizer Profit & Loss

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Net Sales	1853	2012	1966	1969	2082	2152	2239	2611	2425	2193	2281	2282
Other Income	72	87	101	114	167	184	81	63	101	181	172	173
Total Income	1925	2099	2067	2083	2249	2336	2320	2674	2526	2374	2454	2454
Total Expenditure	1474	1579	1616	1468	1516	1579	1526	1775	1616	1558	1541	1540
Operating Profit	451	520	451	615	733	757	794	899	910	816	913	912
Interest	2	1	2	1	2	11	15	11	13	15	9	9
Depreciation	131	58	63	66	71	103	109	115	106	62	61	61
Exceptional Income / Expenses	-80	10	130	0	0	0	0	0	33	8	173	173
Profit Before Tax	238	470	517	548	660	642	669	773	824	746	1016	1016
Provision for Tax	138	165	180	188	231	133	171	160	200	195	248	249
Profit After Tax	100	305	337	360	429	509	498	613	624	551	768	768
Adjustments	-31	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	70	305	337	360	429	509	498	613	624	551	768	768
Adjusted Earnings Per Share	21.9	66.7	73.6	78.7	93.8	111.3	108.8	133.9	136.4	120.5	167.8	167.7

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	4%	-4%	1%	2%
Operating Profit CAGR	12%	1%	4%	7%
PAT CAGR	39%	8%	9%	23%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	11%	10%	6%	10%
ROE Average	20%	19%	19%	16%
ROCE Average	26%	25%	26%	23%

Pfizer Balance Sheet

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Shareholder's Funds	1973	2163	2419	2683	3011	3395	2393	2864	3207	3596	4217
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	3	3	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-37	64	62	52	37	136	85	136	38	33	55
Total Current Liabilities	609	658	780	954	892	873	774	853	657	547	570
Total Liabilities	2547	2888	3261	3690	3940	4405	3252	3854	3903	4175	4842
Fixed Assets	944	925	867	917	854	942	865	841	749	713	724
Other Non-Current Assets	350	331	343	357	371	415	479	616	629	693	605
Total Current Assets	1252	1614	2033	2403	2702	3013	1873	2361	2493	2738	3513
Total Assets	2547	2888	3261	3690	3940	4405	3252	3854	3903	4175	4842

Pfizer Cash Flow

#(Fig in Cr.)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Opening Cash & Cash Equivalents	308	488	71	68	51	74	1764	151	63	37	112
Cash Flow from Operating Activities	113	345	329	332	98	323	427	667	356	257	660
Cash Flow from Investing Activities	-89	-701	-250	-238	35	1530	-469	-575	-36	54	-71
Cash Flow from Financing Activities	-1	-62	-83	-110	-110	-164	-1571	-181	-346	-235	-205
Net Cash Inflow / Outflow	23	-417	-3	-17	23	1690	-1613	-88	-26	75	383
Closing Cash & Cash Equivalent	488	71	68	51	74	1764	151	63	37	112	495

Pfizer Ratios

#	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Earnings Per Share (Rs)	21.93	66.67	73.61	78.7	93.78	111.29	108.77	133.89	136.38	120.51	167.78
CEPS(Rs)	50.59	79.33	87.37	93.18	109.39	133.85	132.68	159.03	159.44	134.12	181.07
DPS(Rs)	12.5	15	20	20	22.5	330	35	30	70	35	165
Book NAV/Share(Rs)	431.28	472.92	528.72	586.49	658.22	742.18	523.07	626.1	701.05	785.91	921.84
Core EBITDA Margin(%)	19.69	20.67	17.15	25.28	27.17	26.62	31.82	30.79	31.6	27.43	31.01
EBIT Margin(%)	12.43	22.53	25.41	27.71	31.79	30.37	30.56	28.86	32.71	32.88	42.91
Pre Tax Margin(%)	12.36	22.47	25.31	27.67	31.7	29.86	29.87	28.46	32.18	32.21	42.56
PAT Margin (%)	5.21	14.57	16.49	18.18	20.61	23.66	22.23	22.56	24.37	23.81	32.15
Cash Profit Margin (%)	12.01	17.33	19.58	21.53	24.04	28.46	27.12	26.79	28.49	26.49	34.7
ROA(%)	5.75	11.22	10.95	10.36	11.25	12.2	13	17.24	16.09	13.65	17.03
ROE(%)	7.63	14.75	14.7	14.11	15.07	15.89	17.19	23.3	20.55	16.21	19.65
ROCE(%)	18.19	22.78	22.62	21.49	23.22	20.38	23.62	29.78	27.56	22.37	26.21
Receivable days	31.59	26.35	22.58	24.43	28.62	29.15	22.89	16.89	20.98	26.74	29.1
Inventory Days	51.1	65.25	61.01	57.05	59.95	69.32	70.57	59.41	61.77	67.09	69.53
Payable days	138.79	175.52	186.15	238.01	250.57	212.28	176.59	114.15	109.36	95.85	76.77
PER(x)	101.69	26.8	25.71	27.77	35.41	36.17	41.57	32.5	25.4	34.8	23.86
Price/Book(x)	5.17	3.78	3.58	3.73	5.04	5.42	8.64	6.95	4.94	5.34	4.34
Dividend Yield(%)	0.56	0.84	1.06	0.92	0.68	8.2	0.77	0.69	2.02	0.83	4.12
EV/Net Sales(x)	5.18	3.55	3.63	4.18	6.38	7.53	8.74	7	5.77	7.82	6.8
EV/Core EBITDA(x)	21.28	13.76	15.82	13.38	18.12	21.4	24.67	20.33	15.37	21.01	17.01
Net Sales Growth(%)	66.69	8.58	-2.29	0.11	5.74	3.37	4.04	16.64	-7.13	-9.55	4.02
EBIT Growth(%)	-29.69	96.98	9.96	5.76	20.59	-1.23	4.68	14.54	6.88	-9.07	34.55
PAT Growth(%)	-54.57	203.95	10.43	6.92	19.16	18.66	-2.26	23.1	1.86	-11.64	39.23
EPS Growth(%)	-70.36	203.95	10.42	6.92	19.16	18.66	-2.26	23.1	1.86	-11.64	39.23
Debt/Equity(x)	0	0	0	0	0	0	0	0	0	0	0
Current Ratio(x)	2.06	2.45	2.61	2.52	3.03	3.45	2.42	2.77	3.79	5.01	6.17
Quick Ratio(x)	1.42	1.9	2.19	2.21	2.6	2.96	1.87	2.24	3.16	4.22	5.33
Interest Cover(x)	158.68	337.93	264.69	712.57	384.67	59.36	44.45	73.23	62.13	49.35	120.54
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Pfizer Shareholding Pattern

#	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Promoter	63.92	63.92	63.92	63.92	63.92	63.92	63.92	63.92	63.92	63.92
FII	2.77	2.8	2.81	2.82	3.03	3.32	3.22	3.54	2.75	2.18
DII	14.93	14.9	14.89	15.01	15.15	15.33	15.84	16.03	16.79	17.1
Public	18.38	18.38	18.38	18.25	17.9	17.42	17.02	16.5	16.54	16.8
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Promoter	2.92	2.92	2.92	2.92	2.92	2.92	2.92	2.92	2.92	2.92
FII	0.13	0.13	0.13	0.13	0.14	0.15	0.15	0.16	0.13	0.1
DII	0.68	0.68	0.68	0.69	0.69	0.7	0.72	0.73	0.77	0.78
Public	0.84	0.84	0.84	0.83	0.82	0.8	0.78	0.76	0.76	0.77
Others	0	0	0	0	0	0	0	0	0	0
Total	4.57	4.57	4.57	4.57	4.57	4.57	4.57	4.57	4.57	4.57

Pros

Debtor days have improved from 95.85 to 76.77days.
Company is almost debt free.

Cons

Stock is trading at 6 times its book value.
The company has delivered a poor profit growth of 8% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Pfizer News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Pfizer

Add Watchlist

Pfizer Research see more...

Overview Inc. Year: 1950Industry: Pharmaceuticals & Drugs

Pfizer Share Price

Alert Data

Quarterly Price

Peer Comparison

Pfizer Quarterly Results

Pfizer Profit & Loss

Growth Rates

Pfizer Balance Sheet

Pfizer Cash Flow

Pfizer Ratios

Pfizer Shareholding Pattern

Pfizer News

IPO

Sharescart: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!

Enter Your Complaint